Guizhou Yibai Pharmaceutical Co Ltd Net Asset Quality Index
Guizhou Yibai Pharmaceutical Co Ltd net asset quality index. Guizhou Yibai Pharmaceutical Co Ltd (600594) has a Net Asset Quality Index of 67.1% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.27 Billion minus total liabilities of CN¥1.07 Billion yields net assets of CN¥2.19 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Guizhou Yibai Pharmaceutical Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Guizhou Yibai Pharmaceutical Co Ltd (2001–2025)
Net asset quality index of Guizhou Yibai Pharmaceutical Co Ltd from 2001 to 2025. This chart shows how Guizhou Yibai Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 25 annual periods from 2001 to 2025. As of June 2026, the index stands at 67.1%, representing net assets of CN¥2.19 Billion against total assets of CN¥3.27 Billion CNY. See Guizhou Yibai Pharmaceutical Co Ltd (600594) shareholders funds for net asset value and shareholders' equity analysis.
Guizhou Yibai Pharmaceutical Co Ltd Net Asset Quality Index by Year (2001–2025)
Guizhou Yibai Pharmaceutical Co Ltd net asset quality index by year from 2001 to 2025. The table below presents the year-by-year Net Asset Quality Index for Guizhou Yibai Pharmaceutical Co Ltd from 2001 to 2025, covering 25 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see how much is Guizhou Yibai Pharmaceutical Co Ltd worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 66.0% | CN¥2.27 Billion | CN¥3.44 Billion | CN¥1.17 Billion | ▲ +2.4 pp |
| 2024 | 63.6% | CN¥2.61 Billion | CN¥4.10 Billion | CN¥1.49 Billion | ▼ -2.1 pp |
| 2023 | 65.7% | CN¥3.02 Billion | CN¥4.60 Billion | CN¥1.58 Billion | ▲ +0.1 pp |
| 2022 | 65.6% | CN¥3.19 Billion | CN¥4.87 Billion | CN¥1.68 Billion | ▼ -4.7 pp |
| 2021 | 70.3% | CN¥3.56 Billion | CN¥5.07 Billion | CN¥1.51 Billion | ▲ +4.0 pp |
| 2020 | 66.3% | CN¥3.46 Billion | CN¥5.23 Billion | CN¥1.76 Billion | ▼ 0.0 pp |
| 2019 | 66.3% | CN¥3.72 Billion | CN¥5.62 Billion | CN¥1.89 Billion | ▲ +5.9 pp |
| 2018 | 60.4% | CN¥3.91 Billion | CN¥6.48 Billion | CN¥2.56 Billion | ▼ -4.1 pp |
| 2017 | 64.5% | CN¥4.64 Billion | CN¥7.19 Billion | CN¥2.55 Billion | ▲ +0.9 pp |
| 2016 | 63.6% | CN¥4.19 Billion | CN¥6.59 Billion | CN¥2.40 Billion | ▲ +0.1 pp |
| 2015 | 63.5% | CN¥3.55 Billion | CN¥5.59 Billion | CN¥2.04 Billion | ▲ +1.2 pp |
| 2014 | 62.3% | CN¥3.42 Billion | CN¥5.50 Billion | CN¥2.07 Billion | ▲ +1.9 pp |
| 2013 | 60.4% | CN¥1.93 Billion | CN¥3.20 Billion | CN¥1.27 Billion | ▼ -7.5 pp |
| 2012 | 67.9% | CN¥1.55 Billion | CN¥2.28 Billion | CN¥731.33 Million | ▲ +4.8 pp |
| 2011 | 63.1% | CN¥1.14 Billion | CN¥1.80 Billion | CN¥665.51 Million | ▲ +7.1 pp |
| 2010 | 56.0% | CN¥876.05 Million | CN¥1.56 Billion | CN¥688.82 Million | ▲ +0.5 pp |
| 2009 | 55.4% | CN¥710.95 Million | CN¥1.28 Billion | CN¥571.26 Million | ▲ +6.4 pp |
| 2008 | 49.1% | CN¥598.16 Million | CN¥1.22 Billion | CN¥620.62 Million | ▲ +2.6 pp |
| 2007 | 46.5% | CN¥530.04 Million | CN¥1.14 Billion | CN¥610.24 Million | ▲ +3.4 pp |
| 2006 | 43.1% | CN¥425.69 Million | CN¥987.97 Million | CN¥562.27 Million | ▼ -2.5 pp |
| 2005 | 45.6% | CN¥547.39 Million | CN¥1.20 Billion | CN¥652.65 Million | ▼ -12.8 pp |
| 2004 | 58.4% | CN¥506.70 Million | CN¥867.80 Million | CN¥361.10 Million | ▲ +18.8 pp |
| 2003 | 39.6% | CN¥180.22 Million | CN¥455.14 Million | CN¥274.93 Million | ▼ -2.7 pp |
| 2002 | 42.3% | CN¥128.20 Million | CN¥303.07 Million | CN¥174.87 Million | ▲ +4.4 pp |
| 2001 | 37.9% | CN¥82.63 Million | CN¥217.81 Million | CN¥135.18 Million | — |